Galera Therapeutics (GRTX) Competitors $0.02 0.00 (-4.12%) As of 03:41 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock GRTX vs. TRAW, OMGA, INDP, GNPX, AIM, CHRO, BFRI, ALBT, SNGX, and AEZSShould you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Traws Pharma (TRAW), Omega Therapeutics (OMGA), Indaptus Therapeutics (INDP), Genprex (GNPX), AIM ImmunoTech (AIM), Chromocell Therapeutics (CHRO), Biofrontera (BFRI), Avalon GloboCare (ALBT), Soligenix (SNGX), and Aeterna Zentaris (AEZS). These companies are all part of the "pharmaceutical products" industry. Galera Therapeutics vs. Traws Pharma Omega Therapeutics Indaptus Therapeutics Genprex AIM ImmunoTech Chromocell Therapeutics Biofrontera Avalon GloboCare Soligenix Aeterna Zentaris Galera Therapeutics (NASDAQ:GRTX) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, community ranking, dividends, risk and analyst recommendations. Is GRTX or TRAW more profitable? Galera Therapeutics has a net margin of 0.00% compared to Traws Pharma's net margin of -62,294.25%. Company Net Margins Return on Equity Return on Assets Galera TherapeuticsN/A N/A -99.34% Traws Pharma -62,294.25%N/A -822.38% Which has better valuation & earnings, GRTX or TRAW? Traws Pharma has higher revenue and earnings than Galera Therapeutics. Galera Therapeutics is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalera TherapeuticsN/AN/A-$59.08M-$0.35-0.07Traws Pharma$226K29.74-$18.95M-$32.81-0.04 Does the MarketBeat Community prefer GRTX or TRAW? Galera Therapeutics received 50 more outperform votes than Traws Pharma when rated by MarketBeat users. CompanyUnderperformOutperformGalera TherapeuticsOutperform Votes5054.35% Underperform Votes4245.65% Traws PharmaN/AN/A Do institutionals & insiders believe in GRTX or TRAW? 50.8% of Galera Therapeutics shares are held by institutional investors. Comparatively, 7.9% of Traws Pharma shares are held by institutional investors. 12.9% of Galera Therapeutics shares are held by company insiders. Comparatively, 13.6% of Traws Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, GRTX or TRAW? Galera Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Traws Pharma has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Does the media prefer GRTX or TRAW? In the previous week, Traws Pharma had 2 more articles in the media than Galera Therapeutics. MarketBeat recorded 2 mentions for Traws Pharma and 0 mentions for Galera Therapeutics. Traws Pharma's average media sentiment score of 0.96 beat Galera Therapeutics' score of 0.00 indicating that Traws Pharma is being referred to more favorably in the news media. Company Overall Sentiment Galera Therapeutics Neutral Traws Pharma Positive SummaryGalera Therapeutics and Traws Pharma tied by winning 6 of the 12 factors compared between the two stocks. Get Galera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRTX vs. The Competition Export to ExcelMetricGalera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.76M$6.50B$5.34B$8.42BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-0.079.1526.8519.72Price / SalesN/A252.36387.23121.26Price / CashN/A65.8538.2534.62Price / Book-0.016.456.774.51Net Income-$59.08M$144.21M$3.23B$248.32M7 Day PerformanceN/A2.38%1.81%0.60%1 Month PerformanceN/A4.50%10.93%13.18%1 Year PerformanceN/A-2.75%17.15%7.39% Galera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRTXGalera TherapeuticsN/A$0.02-4.1%N/A-87.2%$1.76MN/A-0.0730TRAWTraws Pharma1.0005 of 5 stars$1.39+4.5%N/AN/A$7.09M$226,000.00-0.0117Positive NewsEarnings ReportGap UpOMGAOmega Therapeutics2.2977 of 5 stars$0.13-21.8%$9.20+7,260.0%-94.3%$6.92M$8.10M-0.09120News CoverageGap UpINDPIndaptus Therapeutics2.7076 of 5 stars$0.42+3.9%$8.50+1,941.8%-83.8%$6.68MN/A-0.246Gap DownGNPXGenprex0.9034 of 5 stars$0.28-3.3%$10.00+3,523.2%-88.2%$6.67MN/A0.0020AIMAIM ImmunoTech1.4317 of 5 stars$0.09-22.3%$2.75+2,908.8%-77.7%$6.61M$170,000.00-0.1920Gap DownHigh Trading VolumeCHROChromocell TherapeuticsN/A$1.08-1.9%N/A-46.8%$6.59MN/A-0.734Gap DownBFRIBiofrontera2.6785 of 5 stars$0.68-1.8%$7.00+925.6%-42.1%$6.45M$37.32M-0.3070Earnings ReportAnalyst ForecastAnalyst RevisionGap UpALBTAvalon GloboCare0.567 of 5 stars$3.87-0.5%N/A-11.0%$6.39M$1.33M-0.195Positive NewsUpcoming EarningsSNGXSoligenix0.9773 of 5 stars$1.96-1.3%N/A-68.8%$6.38M$840,000.00-0.2620AEZSAeterna ZentarisN/A$3.55+5.0%N/A-57.0%$6.37M$2.37M-0.2420Analyst Forecast Related Companies and Tools Related Companies TRAW Competitors OMGA Competitors INDP Competitors GNPX Competitors AIM Competitors CHRO Competitors BFRI Competitors ALBT Competitors SNGX Competitors AEZS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRTX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GRTX Stock Free GRTX Stock Alerts